Evidence map›Paper›PMID 32586947›Full record

ArticleDisease models & mechanisms2020

Early evidence of delayed oligodendrocyte maturation in the mouse model of mucolipidosis type IV.

Molly Mepyans, Livia Andrzejczuk, Jahree Sosa, Sierra Smith, Shawn Herron, Samantha DeRosa, Susan A Slaugenhaupt, Albert Misko, Yulia Grishchuk, Kirill Kiselyov

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease models & mechanisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. TRPML-1 Dysfunction and Renal Tubulopathy in Mucolipidosis Type IV.Journal of the American Society of Nephrology : JASN · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Molly MepyansCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Livia AndrzejczukDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Jahree SosaDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Sierra SmithCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Shawn HerronCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Samantha DeRosaCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Susan A SlaugenhauptCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Albert MiskoCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Yulia GrishchukCenter for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA ygrishchuk@partners.org kiselyov@pitt.edu.ORCID 0000-0002-4684-4159
Kirill KiselyovDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA ygrishchuk@partners.org kiselyov@pitt.edu.ORCID 0000-0001-6683-2895
Harvard University · USUniversity of Pittsburgh · US

Funding

From brain iron deficiency to therapeutic opportunities in mucolipidosis IVR01NS096755 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CONNOR, JAMES ROBERT, KISELYOV, KIRILL · 2016 to 2019
$1.7M
NINDS NIH HHS R01 NS096755
6 · The paper itself

Abstract

Mucolipidosis type IV (MLIV) is a lysosomal disease caused by mutations in the

Indexed as

Cell DifferentiationAge FactorsAnimalsBrainCerebellumCerebral CortexDisease Models, AnimalGene Expression Regulation, DevelopmentalMice, Inbred C57BLMice, KnockoutMucolipidosesMyelin-Associated GlycoproteinMyelin Basic ProteinMyelin ProteinsOligodendrocyte Precursor CellsOligodendrogliaMag protein, mouseMbp protein, mouseMcoln1 protein, mouseMobp protein, mouseMyelin-Associated GlycoproteinMyelin Basic ProteinMyelin ProteinsTransient Receptor Potential ChannelsLysosomeMucolipidosis type IVMucolipin-1MyelinationOligodendrocyteTRPML1

Identifiers

PMID32586947
PMCPMC7406328
OpenAlexW3038012698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.